Evidence map›Paper›PMID 31134563›Full record

SynthesisPaediatric drugs2019

Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.

Basmah H Alfageh, Zixuan Wang, Pajaree Mongkhon, Frank M C Besag, Tariq M Alhawassi, Ruth Brauer, Ian C K Wong

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Paediatric drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Article
  7. Autism spectrum disorder and co-occurring schizophrenia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Basmah H AlfagehSchool of Pharmacy, University College London, London, UK.ORCID http://orcid.org/0000-0003-3051-9017
Zixuan WangSchool of Pharmacy, University College London, London, UK.
Pajaree MongkhonSchool of Pharmacy, University College London, London, UK.
Frank M C BesagSchool of Pharmacy, University College London, London, UK.ORCID http://orcid.org/0000-0002-4530-7933
Tariq M AlhawassiCollege of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Ruth BrauerSchool of Pharmacy, University College London, London, UK.
Ian C K WongSchool of Pharmacy, University College London, London, UK. wongick@hku.hk.ORCID http://orcid.org/0000-0001-8242-0014
King Saud University · SAUniversity College London · GBEast London NHS Foundation Trust · GBThe London College · GBUniversity of Phayao · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntipsychotic medication is a commonly prescribed drug class in individuals with autism spectrum disorder (ASD). However, the safety of these agents has not been fully assessed.

objectiveOur objective was to investigate the safety and tolerability profile of antipsychotics in individuals with ASD.

methodsThe Cochrane Library, MEDLINE, Embase and PsycINFO databases were searched up to January 2018. We included studies that reported adverse events (AEs) in participants with ASD taking first- or second-generation antipsychotic medication. The studies included in the analysis were randomized controlled trials (RCTs) and observational studies that were comparative or noncomparative and published as full text in the English language. The primary outcome of this review was AEs of any severity reported with antipsychotic use at any dose. Meta-analysis was performed on studies with child and adolescent participants to estimate the pooled prevalence of the overall AEs and the relative risk (RR) of AEs associated with antipsychotic use using a random-effects model. The Cochrane Collaboration tool and the modified Newcastle-Ottawa Scale (NOS) were used to assess the risk of bias of the included RCTs and observational studies, respectively.

resultsIn total, 54 citations fulfilled the inclusion criteria, of which 40 were RCTs and 14 were observational studies; eight RCTs were included in the meta-analysis to estimate the RR of AEs associated with antipsychotic use and seven observational studies were included to estimate the pooled prevalence of AEs. The RR of AEs with antipsychotic treatment was 22% higher than with placebo (RR 1.22; 95% confidence interval [CI] 1.11-1.34; I

conclusionAntipsychotic-related AEs were common among patients with ASD. Further studies to investigate the implications of antipsychotic-related AEs on health and medication adherence are warranted. PROSPERO registration number: (CRD42018083632).

Indexed as

AdolescentAntipsychotic AgentsAutism Spectrum DisorderChildHumansAntipsychotic Agents

Identifiers

PMID31134563
OpenAlexW2947645951

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.